Radiopharmaceuticals for bone metastasis therapy and beyond: A voyage from the past to the present and a look to the future

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 535-551

  Ferreira, Sara ^a,b   Dormehl, Irene ^c   Botelho, Maria Filomena ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Bone metastases; Radionuclide therapy; Radiopharmaceuticals; Targeted therapy; Treatment

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CISPLATIN; COPPER 67; DOCETAXEL; ETIDRONIC ACID; INDIUM 111; IODINE 125; LEXIDRONAM SAMARIUM SM 153; MEDRONATE TECHNETIUM TC 99M; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RADIUM CHLORIDE RA 223; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; YTTRIUM 90;

ADVANCED CANCER; AUGER ELECTRON SPECTROSCOPY; BONE DEVELOPMENT; BONE MARROW TOXICITY; BONE METABOLISM; BONE METASTASIS; BONE MINERAL; BREAST CANCER; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC PAIN; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; DRUG HALF LIFE; EXTRACELLULAR MATRIX; HUMAN; ISOTOPE LABELING; NERVE ROOT COMPRESSION; NOCICEPTIVE PAIN; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PERMEABILITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SOCIAL ENVIRONMENT; SPINE METASTASIS; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANIMALS; BONE NEOPLASMS; HUMANS; OSTEOSARCOMA; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 84868276649     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1258     Document Type: Review

References (112)

1. Liotta LA. An attractive force in metastasis. Nature 2001; 410:24.
2. Christian P, Waterstram R. Nuclear Medicine and PET/CT: Technologies and Techniques, 6th. edition. St. Louis: Elsevier, 2007.
3. Damjanov I. Pathology for Health-Related Professions, 2nd edition. Philadelphia: Saunders, 2000.
4. Spangler JG. Bone biology and physiology: Implications for novel osteoblastic osteosarcoma treatments? Med Hypotheses 2008;70:281.
5. Dormehl IC, Louw WK, Milner RJ, et al. Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. Arzneimittelforschung 2001;51:258.
6. Ridone S, Bonardi ML, Groppi F, et al. Paper radiochromatography for evaluation of radiochemical purity and stability of [186gRe]Re-HEDP in biological samples after human administration. J Radioanal Nucl Chem 2008;277:117.
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12: 6243s.
8. Palmedo H. Radionuclid therapy of bone metastases. In: Biersack HJ, Freeman LM, eds. Clinical Nuclear Medicine. New York: Springer, 2007;433.
9. Paterson AH. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8 Suppl 1987;1:S17.
10. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21:337.
11. Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). Int J Mol Med 2007;20:103.
12. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50.
13. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991; 9:509.
14. Zeevaart JR, Louw WKA, Kolar ZI, et al. A thermodynamic approach, using speciation studies, towards the evaluation and design of bone-seeking radiopharmaceuticals as illustrated for 117mSn(II)-PEI-MP. J Radioanal Nucl Chem 2003; 257:83.
15. Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol Rev 1987;67:67.
16. Mense S. Sensitization of group IV muscle receptors to bradykinin by 5-hydroxytryptamine and prostaglandin E2. Brain Res 1981;225:95.
17. Bagi CM. Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 2005;57:995.
18. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977; 39:1289.
19. WHO Expert Committee on Cancer Pain Relief and Active Supportive Care. World Health Organization. Cancer pain relief and palliative care: Report of a WHO expert committee [meeting held in Geneva from 3 to 10 July 1989]. Geneva: World Health Organization, 1990.
20. Jansen D, Zeevaart J, Kolar Z, et al. 31P NMR study of the valence stability of tin in its 1-hydroxyethylene-diphosphonate (HEDP) and N,N0,N0-trimethylenephosphonatepolyethyleneimine (PEI-MP) complexes. Polyhedron 2008; 27:1779.
21. Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol 2001;40:239.
22. Yoneda T, Michigami T, Yi B, et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999;25:293.
23. Thurlimann B, Morant R, Jungi WF, et al. Pamidronate for pain control in patients with malignant osteolytic bone disease: A prospective dose-effect study. Support Care Cancer 1994;2:61.
24. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000; 10:240.
25. Hoskin PJ, Price P, Easton D, et al. A prospective randomised trial of 4Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992;23:74.
26. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999;353:267.
27. Hanks GE. Conformal radiotherapy for prostate cancer. Ann Med 2000;32:57.
28. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993;20:66.
29. Porter AT, Ben-Josef E, Davis L. Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium. Curr Opin Oncol 1994; 6:607.
30. Lin WY, Lin CP, Yeh SJ, et al. Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997;24:590.
31. Liepe K, Kropp J, Runge R, et al. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003;89:625.
32. de Klerk JM, van Dijk A, van het Schip AD, et al. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992;33:646.
33. Nayak D, Lahiri S. Application of radioisotopes in the field of nuclear medicine. J Radioanal Nucl Chem 1999;242:423.
34. Stigbrand T, Adams JG. Targeted Radionuclide Tumor Therapy: Biological Aspects. New York: Springer, 2008.
35. Lisic EC, Phillips M, Ensor D, et al. Synthesis of a new bisphosphonic acid ligand (SEDP) and preparation of a (188)Re-(Sn)SEDP bone seeking radiotracer. Nucl Med Biol 2001;28:419.
36. Rizkalla EN, Zaki MT. Metal chelates of phosphonatecontaining ligands. Rev Inorg Chem 1983;5:223.
37. Jurisson S, Berning D, Jia W, et al. Coordination compounds in nuclear medicine. Chem Rev 1993;93:1137.
38. Botelho MF, Zeevaart JR, Dormehl IC, et al. Dosimetric evaluation of the polyphosphonate (PEI-MP) labeled with 117mSn, 186Re and 99mTc as potential diagnosis/ therapeutic bone agents. Eur J Nucl Med Mol Imaging 2006;33:S309.
39. Degrossi OJ, Oliveri P, Garcia del Rio H, et al. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. J Nucl Med 1985;26:1135.
40. Zeevaart JR, Jarvis NV, Louw WK, et al. Metal-ion speciation in blood plasma incorporating the tetraphosphonate, N,N-dimethylenephosphonate-1-hydroxy- 4-aminopropilydenediphosphonate (APDDMP), in therapeutic radiopharmaceuticals. J Inorg Biochem 2001;83:57.
41. Bevan JA, Tofe AJ, Benedict JJ, et al. Tc-99m HMDP (hydroxymethylene diphosphonate): A radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model. J Nucl Med 1980;21:967.
42. Murray I, Ell PJ. Nuclear Medicine in Clinical Diagnosis and Treatment, 2nd edition. China: Churchill Livingstone, 1998.
43. Wessels BW, Meares CF. Physical and chemical properties of radionuclide therapy. Semin Radiat Oncol 2000;10:115.
44. Lattimer JC, Corwin LA, Jr., Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med 1990; 31:1316.
45. Volkert WA, Goeckeler WF, Ehrhardt GJ, et al. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 1991;32:174.
46. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120.
47. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33.
48. Srivastava SC. Bone-seeking therapeutic radiopharmaceuticals. Braz Arch Biol Technol 2002;45:45.
49. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816.
50. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954.
51. Blake GM, Zivanovic MA, McEwan AJ, et al. 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 1987;13:41.
52. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447.
53. Atkins HL, Mausner LF, Srivastava SC, et al. Biodistribution of Sn-117m(4 +) DTPA for palliative therapy of painful osseous metastases. Radiology 1993;186:279.
54. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27:1084.
55. Ketring AR. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B 1987;14:223.
56. Holmes RA. [153Sm]EDTMP: A potential therapy for bone cancer pain. Semin Nucl Med 1992;22:41.
57. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451.
58. Alberts AS, Smit BJ, Louw WK, et al. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175.
59. Hsieh BT, Hsieh JF, Tsai SC, et al. Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. Nucl Med Biol 1999;26:973.
60. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574.
61. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26:2.
62. Collins C, Eary JF, Donaldson G, et al. Samarium-153-Edtmp in bone metastases of hormone-refractory prostate carcinoma - A phase-I/Ii trial. J Nucl Med 1993;34:1839.
63. Maxon HR, Deutsch EA, Thomas SR, et al. Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies. Radiology 1988;166:501.
64. Robinson RG. Strontium-89 - precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993; 72:3433.
65. Baziotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998;55:377.
66. Hauswirth AE, Palmedo H, Dierke-Dzierzon C, et al. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP]. Zentralbl Gynakol 1998;120:83.
67. Han SH, Zonneberg BA, de Klerk JM, et al. 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 1999;40:639.
68. Li S, Liu J, Zhang H, et al. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001;26:919.
69. Boschi A, Bolzati C, Uccelli L, et al. High-yield synthesis of the terminal 188Re triple bond N multiple bond from generator-produced [188ReO4] (-) . Nucl Med Biol 2003;30:381.
70. Deutsch E, Libson K, Vanderheyden JL, et al. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclearmedicine. Int J Rad Appl Instrum B 1986;13:465.
71. Elder RC, Yuan J, Helmer B, et al. Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogues of the radiotherapeutic agent (186)ReHEDP. Inorg Chem 1997;36:3055.
72. Weinger JA, Ketring AR, Deutsch EA. 186Re-HEDP: A potential therapeutic bone agent. Nuklearmedizin 1984;23:81
73. Lin WY, Hsieh JF, Lin CP, et al. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes. Nucl Med Biol 1999;26:455.
74. Eisenhut M. Preparation of 186Re-perrhenate for nuclear medical purposes. Int J Appl Radiat Isot 1982;33:99.
75. Knapp FF, Jr. Rhenium-188 - A generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 1998;13:337.
76. Hruby M, Etrych T, Kucka J, et al. Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue. J Appl Polym Sci. 2006;101:3192.
77. Antoccia A, Baldazzi G, Bello M, et al. Preliminary study of metabolic radiotherapy with Re-188 via small animal imaging. Nucl Phys B-Proc Suppl 2006;150:411.
78. Saha G. Fundamentals of Nuclear Pharmacy. New York: Springer, 1998.
79. Knapp FF, Jr., Beets AL, Guhlke S, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997;17:1783.
80. Wang SJ, Lin WY, Chen MN, et al. Histologic study of effects of radiation synovectomy with Rhenium-188 microsphere. Nucl Med Biol 2001;28:727.
81. Chen FD, Hsieh BT, Wang HE, et al. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl Med Biol 2001;28:835.
82. Cherry S, Sorenson J, Phelps M. Appendix C: Characteristics of some medically important radionuclides. In: Physics in Nuclear Medicine, 3rd edition. New York: Saunders Elsevier, 2003, 449.
83. El-Mabhouh A, Mercer Jr. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isot 2005;62:541.
84. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989;30:1814.
85. Ogawa K, Kawashima H, Shiba K, et al. Development of [(90)Y]DOTA- conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 2009;36:129.
86. Rajendram JG. Therapeutic radioisotope. In: Eary JF, ed., Nuclear Medicine Therapy. New York: Informa Healthcare, 2007;9.
87. Bryan JN, Bommarito D, Kim DY, et al. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. J Nucl Med Technol 2009;37:45.
88. Das T, Chakraborty S, Unni PR, et al. Lu-177-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 2002;57:177.
89. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858.
90. Hall EJ. Radiobiology for the Radiologist. Philadelphia: Lippincott, Williams & Wilkins, 2000.
91. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451.
92. Kvinnsland Y, Skretting A, Bruland OS. Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. Phys Med Biol 2001;46:1149.
93. Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44:252.
94. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587.
95. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol Suppl 2012;30.
96. Parker C, Heinrich D, Helle SI, et al. Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castrationresistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA). Eur Urol Suppl 2012;11:E130.
97. Zeevaart JR, Jansen DR, Botelho MF, et al. Comparison of the predicted in vivo behaviour of the Sn(II)-APDDMP complex and the results as studied in a rodent model. J Inorg Biochem 2004;98:1521.
98. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271.
99. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992;9:135.
100. Hoste K, De Winne K, Schacht E. Polymeric prodrugs. Int J Pharm 2004;277:119.
101. Jansen DR, Krijger GC,Wagener J, et al. Blood plasma model predictions for the proposed bone-seeking radiopharmaceutical [(117m)Sn]Sn(IV)-N,N¢, N¢-trimethylenephosphonatepoly (ethyleneimine). J Inorg Biochem 2009;103:1265.
102. Lyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812.
103. Uhrich KE, Cannizzaro SM, Langer RS, et al. Polymeric systems for controlled drug release. Chem Rev 1999; 99:3181.
104. Botelho MF, Zeevaart JR, Louw WK, et al. Polyethyleneiminomethyl Phosphonate (PEI-MP) for selectively targeting Bone Malignancies. Eur J Nucl Med Mol Imaging 2003;30:S338.
105. Zeevaart JR, Louw WK, Kolar ZI, et al. Biodistribution and pharmacokinetics of variously molecular sized 117mSn(II)-polyethyleneiminomethyl phosphonate complexes in the normal primate model as potential selective therapeutic bone agents. Arzneimittelforschung 2004;54:340.
106. Jansen DR, Zeevaart JR, Denkova A, et al. Hydroxyapatite chemisorption of N,N¢,N¢-trimethylenephosphonate-poly (ethyleneimine) (PEI-MP) combined with Sn2 + or Sn4 + . Langmuir 2009;25:2790.
107. Gerson BD, Dorfman HD, Norman A, et al. Patterns of localization of 85 strontium in osteosarcoma. A correlative study using gross autoradiography. J Bone Joint Surg Am 1972;54:817.
108. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031.
109. Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med 1992;33:1437.
110. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med 2002;43:79.
111. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000;27:123.
112. Anderson PM, Wiseman GA, Dispenzieri A, et al. Highdose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189.